Can an Oral Immunotherapy Desensitize Children With Peanut Allergy?

Treatment with a peanut-derived investigational biologic oral immunotherapy drug effectively reduced sensitivity in children and adolescents with severe peanut allergy, according to the results of a recent study.

The phase 3 trial involved 551 participants, aged 4 to 55 years, with peanut allergy. The participants were screened using a challenge dose of 100 mg or less of peanut protein in a double-blind, placebo-controlled food challenge. They were randomly assigned (3:1) to either receive oral immunotherapy or placebo. Those that completed the escalating-dose program went on to participate in a double-blind, placebo-controlled food challenge at trial exit.

Of the 551 total participants, 496 participants who were 4 to 17 years of age. Of these, 372 received active treatment and 124 received placebo. Overall, 67.2% of those who received active treatment were able to ingest a dose of 600 mg or more of peanut protein during the exit challenge, compared with 4% of those who received placebo.

“In this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut, treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose-limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo.”

—Michael Potts

For more Pharmacy Learning Network articles, visit the homepage

To learn about Pharmacy Learning Network Live meetings, click here